Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications: Analysis of Percent Time in Therapeutic Range
BACKGROUND—Triple antithrombotic therapy increases the risk of bleeding events in patients undergoing percutaneous coronary intervention. However, it remains unclear whether good control of percent time in therapeutic range is associated with reduced occurrence of bleeding complications in patients...
Gespeichert in:
| Veröffentlicht in: | Circulation. Cardiovascular interventions 2013-08, Vol.6 (4), p.444-451 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 451 |
|---|---|
| container_issue | 4 |
| container_start_page | 444 |
| container_title | Circulation. Cardiovascular interventions |
| container_volume | 6 |
| creator | Naruse, Yoshihisa Sato, Akira Hoshi, Tomoya Takeyasu, Noriyuki Kakefuda, Yuki Ishibashi, Mayu Misaki, Masako Abe, Daisuke Aonuma, Kazutaka |
| description | BACKGROUND—Triple antithrombotic therapy increases the risk of bleeding events in patients undergoing percutaneous coronary intervention. However, it remains unclear whether good control of percent time in therapeutic range is associated with reduced occurrence of bleeding complications in patients undergoing triple antithrombotic therapy.
METHODS AND RESULTS—This study included 2648 patients (70±11 years; 2037 men) who underwent percutaneous coronary intervention with stent in the Ibaraki Cardiovascular Assessment Study registry and received dual antiplatelet therapy with or without warfarin. Clinical end points were defined as the occurrence of major bleeding complications (MBC), major adverse cardiac and cerebrovascular event, and all-cause death. Among these 2648 patients, 182 (7%) patients received warfarin. After a median follow-up period of 25 months (interquartile range, 15–35 months), MBC had occurred in 48 (2%) patients, major adverse cardiac and cerebrovascular event in 484 (18%) patients, and all-cause death in 206 (8%) patients. Multivariable Cox regression analysis revealed that triple antithrombotic therapy was the independent predictor for the occurrence of MBC (hazard ratio, 7.25; 95% confidence interval, 3.05–17.21; P |
| doi_str_mv | 10.1161/CIRCINTERVENTIONS.113.000179 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1427002365</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1427002365</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3219-6e0f520f321da94608d7536b7e900b9c51355113013452fc0ba62ac145df3b103</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhS0EoqXwCsgLFmymteM4aRALSjTQSGWmGgLbyHFuGhfHTm1H1bwLD4ujGbphw8J_x9-9x_JB6B0l55Rm9KKsdmW1qde7n-tNXW0336PMzgkhNC-eoVNapHSVZyx5_rRPyQl65f09IVHOkpfoJGHx5pLnp-h37dSkAV-ZoMLg7NjaoCSuB3Bi2uPK4zAArkwHE8TJBHzroFMyWIf7OJbbrZSzc2AkYNvjb-I-6p81RMzc4dKOk1ZSBGWN_xB9hN575RfyFpxcOtZqBKzM0RTm5QE7Ye7gNXrRC-3hzXE9Qz--rOvyenWz_VqVVzcryRJarDIgPU9IHw-dKNKMXHY5Z1mbQ0FIW0hOGefxkwhlKU96SVqRJULSlHc9aylhZ-j9oe_k7MMMPjSj8hK0Fgbs7BuaJjkhCct4RD8eUOms9w76ZnJqFG7fUNIs-TT_5BNl1hzyieVvj05zO0L3VPw3kAh8OgCPVgdw_peeH8E1Awgdhv_z-AMfv6Q9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1427002365</pqid></control><display><type>article</type><title>Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications: Analysis of Percent Time in Therapeutic Range</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Naruse, Yoshihisa ; Sato, Akira ; Hoshi, Tomoya ; Takeyasu, Noriyuki ; Kakefuda, Yuki ; Ishibashi, Mayu ; Misaki, Masako ; Abe, Daisuke ; Aonuma, Kazutaka</creator><creatorcontrib>Naruse, Yoshihisa ; Sato, Akira ; Hoshi, Tomoya ; Takeyasu, Noriyuki ; Kakefuda, Yuki ; Ishibashi, Mayu ; Misaki, Masako ; Abe, Daisuke ; Aonuma, Kazutaka ; Ibaraki Cardiovascular Assessment Study (ICAS) Registry</creatorcontrib><description>BACKGROUND—Triple antithrombotic therapy increases the risk of bleeding events in patients undergoing percutaneous coronary intervention. However, it remains unclear whether good control of percent time in therapeutic range is associated with reduced occurrence of bleeding complications in patients undergoing triple antithrombotic therapy.
METHODS AND RESULTS—This study included 2648 patients (70±11 years; 2037 men) who underwent percutaneous coronary intervention with stent in the Ibaraki Cardiovascular Assessment Study registry and received dual antiplatelet therapy with or without warfarin. Clinical end points were defined as the occurrence of major bleeding complications (MBC), major adverse cardiac and cerebrovascular event, and all-cause death. Among these 2648 patients, 182 (7%) patients received warfarin. After a median follow-up period of 25 months (interquartile range, 15–35 months), MBC had occurred in 48 (2%) patients, major adverse cardiac and cerebrovascular event in 484 (18%) patients, and all-cause death in 206 (8%) patients. Multivariable Cox regression analysis revealed that triple antithrombotic therapy was the independent predictor for the occurrence of MBC (hazard ratio, 7.25; 95% confidence interval, 3.05–17.21; P<0.001). The time in therapeutic range value did not differ between the patients with and without MBC occurrence (83% [interquartile range, 50%–90%] versus 75% [interquartile range, 58%–87%]; P=0.7). However, the mean international normalized ratio of prothrombin time at the time of MBC occurrence was 3.3±2.1. Triple antithrombotic therapy did not have a predictive value for the occurrence of all-cause death (P=0.1) and stroke (P=0.2).
CONCLUSIONS—Triple antithrombotic therapy predisposes patients to an increased risk of MBC regardless of the time in therapeutic range.</description><identifier>ISSN: 1941-7640</identifier><identifier>EISSN: 1941-7632</identifier><identifier>DOI: 10.1161/CIRCINTERVENTIONS.113.000179</identifier><identifier>PMID: 23941857</identifier><language>eng</language><publisher>United States: American Heart Association, Inc</publisher><subject>Aged ; Atrial Fibrillation - drug therapy ; Drug Therapy, Combination ; Female ; Fibrinolytic Agents - administration & dosage ; Fibrinolytic Agents - adverse effects ; Hemorrhage - epidemiology ; Hemorrhage - etiology ; Humans ; International Normalized Ratio ; Male ; Middle Aged ; Percutaneous Coronary Intervention ; Platelet Aggregation Inhibitors - adverse effects ; Proportional Hazards Models ; Stents ; Stroke - prevention & control ; Time Factors ; Warfarin - adverse effects</subject><ispartof>Circulation. Cardiovascular interventions, 2013-08, Vol.6 (4), p.444-451</ispartof><rights>2013 American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3219-6e0f520f321da94608d7536b7e900b9c51355113013452fc0ba62ac145df3b103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23941857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naruse, Yoshihisa</creatorcontrib><creatorcontrib>Sato, Akira</creatorcontrib><creatorcontrib>Hoshi, Tomoya</creatorcontrib><creatorcontrib>Takeyasu, Noriyuki</creatorcontrib><creatorcontrib>Kakefuda, Yuki</creatorcontrib><creatorcontrib>Ishibashi, Mayu</creatorcontrib><creatorcontrib>Misaki, Masako</creatorcontrib><creatorcontrib>Abe, Daisuke</creatorcontrib><creatorcontrib>Aonuma, Kazutaka</creatorcontrib><creatorcontrib>Ibaraki Cardiovascular Assessment Study (ICAS) Registry</creatorcontrib><title>Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications: Analysis of Percent Time in Therapeutic Range</title><title>Circulation. Cardiovascular interventions</title><addtitle>Circ Cardiovasc Interv</addtitle><description>BACKGROUND—Triple antithrombotic therapy increases the risk of bleeding events in patients undergoing percutaneous coronary intervention. However, it remains unclear whether good control of percent time in therapeutic range is associated with reduced occurrence of bleeding complications in patients undergoing triple antithrombotic therapy.
METHODS AND RESULTS—This study included 2648 patients (70±11 years; 2037 men) who underwent percutaneous coronary intervention with stent in the Ibaraki Cardiovascular Assessment Study registry and received dual antiplatelet therapy with or without warfarin. Clinical end points were defined as the occurrence of major bleeding complications (MBC), major adverse cardiac and cerebrovascular event, and all-cause death. Among these 2648 patients, 182 (7%) patients received warfarin. After a median follow-up period of 25 months (interquartile range, 15–35 months), MBC had occurred in 48 (2%) patients, major adverse cardiac and cerebrovascular event in 484 (18%) patients, and all-cause death in 206 (8%) patients. Multivariable Cox regression analysis revealed that triple antithrombotic therapy was the independent predictor for the occurrence of MBC (hazard ratio, 7.25; 95% confidence interval, 3.05–17.21; P<0.001). The time in therapeutic range value did not differ between the patients with and without MBC occurrence (83% [interquartile range, 50%–90%] versus 75% [interquartile range, 58%–87%]; P=0.7). However, the mean international normalized ratio of prothrombin time at the time of MBC occurrence was 3.3±2.1. Triple antithrombotic therapy did not have a predictive value for the occurrence of all-cause death (P=0.1) and stroke (P=0.2).
CONCLUSIONS—Triple antithrombotic therapy predisposes patients to an increased risk of MBC regardless of the time in therapeutic range.</description><subject>Aged</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fibrinolytic Agents - administration & dosage</subject><subject>Fibrinolytic Agents - adverse effects</subject><subject>Hemorrhage - epidemiology</subject><subject>Hemorrhage - etiology</subject><subject>Humans</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Percutaneous Coronary Intervention</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Proportional Hazards Models</subject><subject>Stents</subject><subject>Stroke - prevention & control</subject><subject>Time Factors</subject><subject>Warfarin - adverse effects</subject><issn>1941-7640</issn><issn>1941-7632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUhS0EoqXwCsgLFmymteM4aRALSjTQSGWmGgLbyHFuGhfHTm1H1bwLD4ujGbphw8J_x9-9x_JB6B0l55Rm9KKsdmW1qde7n-tNXW0336PMzgkhNC-eoVNapHSVZyx5_rRPyQl65f09IVHOkpfoJGHx5pLnp-h37dSkAV-ZoMLg7NjaoCSuB3Bi2uPK4zAArkwHE8TJBHzroFMyWIf7OJbbrZSzc2AkYNvjb-I-6p81RMzc4dKOk1ZSBGWN_xB9hN575RfyFpxcOtZqBKzM0RTm5QE7Ye7gNXrRC-3hzXE9Qz--rOvyenWz_VqVVzcryRJarDIgPU9IHw-dKNKMXHY5Z1mbQ0FIW0hOGefxkwhlKU96SVqRJULSlHc9aylhZ-j9oe_k7MMMPjSj8hK0Fgbs7BuaJjkhCct4RD8eUOms9w76ZnJqFG7fUNIs-TT_5BNl1hzyieVvj05zO0L3VPw3kAh8OgCPVgdw_peeH8E1Awgdhv_z-AMfv6Q9</recordid><startdate>201308</startdate><enddate>201308</enddate><creator>Naruse, Yoshihisa</creator><creator>Sato, Akira</creator><creator>Hoshi, Tomoya</creator><creator>Takeyasu, Noriyuki</creator><creator>Kakefuda, Yuki</creator><creator>Ishibashi, Mayu</creator><creator>Misaki, Masako</creator><creator>Abe, Daisuke</creator><creator>Aonuma, Kazutaka</creator><general>American Heart Association, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201308</creationdate><title>Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications: Analysis of Percent Time in Therapeutic Range</title><author>Naruse, Yoshihisa ; Sato, Akira ; Hoshi, Tomoya ; Takeyasu, Noriyuki ; Kakefuda, Yuki ; Ishibashi, Mayu ; Misaki, Masako ; Abe, Daisuke ; Aonuma, Kazutaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3219-6e0f520f321da94608d7536b7e900b9c51355113013452fc0ba62ac145df3b103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fibrinolytic Agents - administration & dosage</topic><topic>Fibrinolytic Agents - adverse effects</topic><topic>Hemorrhage - epidemiology</topic><topic>Hemorrhage - etiology</topic><topic>Humans</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Percutaneous Coronary Intervention</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Proportional Hazards Models</topic><topic>Stents</topic><topic>Stroke - prevention & control</topic><topic>Time Factors</topic><topic>Warfarin - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naruse, Yoshihisa</creatorcontrib><creatorcontrib>Sato, Akira</creatorcontrib><creatorcontrib>Hoshi, Tomoya</creatorcontrib><creatorcontrib>Takeyasu, Noriyuki</creatorcontrib><creatorcontrib>Kakefuda, Yuki</creatorcontrib><creatorcontrib>Ishibashi, Mayu</creatorcontrib><creatorcontrib>Misaki, Masako</creatorcontrib><creatorcontrib>Abe, Daisuke</creatorcontrib><creatorcontrib>Aonuma, Kazutaka</creatorcontrib><creatorcontrib>Ibaraki Cardiovascular Assessment Study (ICAS) Registry</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naruse, Yoshihisa</au><au>Sato, Akira</au><au>Hoshi, Tomoya</au><au>Takeyasu, Noriyuki</au><au>Kakefuda, Yuki</au><au>Ishibashi, Mayu</au><au>Misaki, Masako</au><au>Abe, Daisuke</au><au>Aonuma, Kazutaka</au><aucorp>Ibaraki Cardiovascular Assessment Study (ICAS) Registry</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications: Analysis of Percent Time in Therapeutic Range</atitle><jtitle>Circulation. Cardiovascular interventions</jtitle><addtitle>Circ Cardiovasc Interv</addtitle><date>2013-08</date><risdate>2013</risdate><volume>6</volume><issue>4</issue><spage>444</spage><epage>451</epage><pages>444-451</pages><issn>1941-7640</issn><eissn>1941-7632</eissn><abstract>BACKGROUND—Triple antithrombotic therapy increases the risk of bleeding events in patients undergoing percutaneous coronary intervention. However, it remains unclear whether good control of percent time in therapeutic range is associated with reduced occurrence of bleeding complications in patients undergoing triple antithrombotic therapy.
METHODS AND RESULTS—This study included 2648 patients (70±11 years; 2037 men) who underwent percutaneous coronary intervention with stent in the Ibaraki Cardiovascular Assessment Study registry and received dual antiplatelet therapy with or without warfarin. Clinical end points were defined as the occurrence of major bleeding complications (MBC), major adverse cardiac and cerebrovascular event, and all-cause death. Among these 2648 patients, 182 (7%) patients received warfarin. After a median follow-up period of 25 months (interquartile range, 15–35 months), MBC had occurred in 48 (2%) patients, major adverse cardiac and cerebrovascular event in 484 (18%) patients, and all-cause death in 206 (8%) patients. Multivariable Cox regression analysis revealed that triple antithrombotic therapy was the independent predictor for the occurrence of MBC (hazard ratio, 7.25; 95% confidence interval, 3.05–17.21; P<0.001). The time in therapeutic range value did not differ between the patients with and without MBC occurrence (83% [interquartile range, 50%–90%] versus 75% [interquartile range, 58%–87%]; P=0.7). However, the mean international normalized ratio of prothrombin time at the time of MBC occurrence was 3.3±2.1. Triple antithrombotic therapy did not have a predictive value for the occurrence of all-cause death (P=0.1) and stroke (P=0.2).
CONCLUSIONS—Triple antithrombotic therapy predisposes patients to an increased risk of MBC regardless of the time in therapeutic range.</abstract><cop>United States</cop><pub>American Heart Association, Inc</pub><pmid>23941857</pmid><doi>10.1161/CIRCINTERVENTIONS.113.000179</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-7640 |
| ispartof | Circulation. Cardiovascular interventions, 2013-08, Vol.6 (4), p.444-451 |
| issn | 1941-7640 1941-7632 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1427002365 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Aged Atrial Fibrillation - drug therapy Drug Therapy, Combination Female Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - adverse effects Hemorrhage - epidemiology Hemorrhage - etiology Humans International Normalized Ratio Male Middle Aged Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - adverse effects Proportional Hazards Models Stents Stroke - prevention & control Time Factors Warfarin - adverse effects |
| title | Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications: Analysis of Percent Time in Therapeutic Range |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A26%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triple%20Antithrombotic%20Therapy%20Is%20the%20Independent%20Predictor%20for%20the%20Occurrence%20of%20Major%20Bleeding%20Complications:%20Analysis%20of%20Percent%20Time%20in%20Therapeutic%20Range&rft.jtitle=Circulation.%20Cardiovascular%20interventions&rft.au=Naruse,%20Yoshihisa&rft.aucorp=Ibaraki%20Cardiovascular%20Assessment%20Study%20(ICAS)%20Registry&rft.date=2013-08&rft.volume=6&rft.issue=4&rft.spage=444&rft.epage=451&rft.pages=444-451&rft.issn=1941-7640&rft.eissn=1941-7632&rft_id=info:doi/10.1161/CIRCINTERVENTIONS.113.000179&rft_dat=%3Cproquest_cross%3E1427002365%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1427002365&rft_id=info:pmid/23941857&rfr_iscdi=true |